News and Announcements
Dragonfly Biosciences ASX Listing Applications are now open
- Published December 08, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Finexia is pleased to advise that the Dragonfly Biosciences initial public offer (IPO) is now open and accepting applications from the public. The company is seeking raise A$10M with the aim of listing on the ASX in late December 2021.
Dragonfly Biosciences Ltd is a vertically integrated ‘seed-to-shelf’ cannabidiol (CBD) business that trades under the Dragonfly CBD brand. The Company owns the entire value chain from their certified organic farms, extraction facilities and state of the art laboratories used for producing premium CBD products.
Dragonfly CBD products have been voted “Best CBD Product” in 2020 by Boots UK, one of the world’s most respected health and beauty retailer and pharmacy chains. Dragonfly’s product distribution extends into national grocery and specialty chains including Tesco, Sanisbury’s and Amazon UK, securing their status as a market leader in the UK and beyond.
The Company is issuing 50M shares at A$0.20 through the IPO and intends to raise A$10M to be deployed for accelerated global expansion and further product development.
Applications close 5.00pm AEST 14 December 2021.
To be part of the exciting journey that is Dragonfly, please obtain a copy of the prospectus via the button below.
Download Replacement Prospectus
About the Company
Dragonfly Biosciences was incorporated on 29 June 2017 and is a premium retailer of cannabidiol (CBD) oil. Through its extensive research and development, Dragonfly controls the process from seed to sale, with the aim of producing the highest and most consistent product quality. Dragonfly currently offers a range of CBD health and lifestyle products.
Dragonfly aims to expand its business and product range in line with legislative changes in Europe, the USA and Australia. As demand grows for CBD health supplements, Dragonfly seeks to be the go-to producer and supplier of CBD for both businesses and consumers.
Dragonfly’s products are tested in third-party laboratories, as well as implementing its own testing regime to ensure consistency and quality across the board with Good Manufacturing Practices (GMP). Its product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a and CBG.
Company Updates
Cosmo Innovations Founder Eyes Global Rollout of SkinGate, IPO by 2027
Dr. Mathew Jafarzadeh, founder of Cosmo Innovations, is set to revolutionize the $65 billion home beauty tech market with SkinGate, a patented skincare infusion device. Following his presentation at Emergence 2025, he revealed plans for a global rollout, aiming for a 2027 IPO on NASDAQ or the Hong Kong Exchange. Discover how SkinGate, backed by 110+ patents, seeks to attract “smart capital” and redefine skincare delivery.
Stop Leaving Millions on the Table: The Investor Secret You’re Missing!
In an Australian business landscape increasingly defined by volatility and intense competition for capital, the art of robust stakeholder relations has evolved beyond a mere governance checkbox. For founders, boards, and executive teams, the ability to genuinely inform and engage investors isn’t just about meeting disclosure requirements; it’s a strategic imperative that directly impacts capital […]
Ecosystems Over Exit: Callum Laing on Disrupting Small Business M&A
At Emergence Singapore, Callum Laing of Veblen Director Program presented a bold new vision for small business M&A: “Ecosystems Over Exit.” He shared how his Unity Group takes cash-generating businesses public, focusing on growth over immediate founder exit. Discover his unique approach, how interconnected ecosystems drive massive deal flow, and a three-step framework for any business to amplify reach and capital raising.
Backed By Leading Investment Groups and Family Offices
